Chemocentryx Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Employees
-
178
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.7B
Chemocentryx General Information
Description
Developer of administered small molecule therapeutics based in Mountain View, California. The company offers orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer.
Contact Information
Website
www.chemocentryx.comCorporate Office
- 850 Maude Avenue
- Mountain View, CA 94043
- United States
Corporate Office
- 850 Maude Avenue
- Mountain View, CA 94043
- United States
Chemocentryx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Merger/Acquisition | 20-Oct-2022 | $3.7B | Completed | Generating Revenue | ||
| 12. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 11. PIPE | 04-Jan-2018 | Completed | Generating Revenue | |||
| 10. PIPE | 11-May-2016 | Completed | Clinical Trials - Phase 3 | |||
| 9. Secondary Transaction - Open Market | 31-Mar-2014 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 28-Mar-2013 | Completed | Generating Revenue | |||
| 7. IPO | 08-Feb-2012 | Completed | Pre-Clinical Trials | |||
| 6. IPO | 14-Nov-2008 | Cancelled | Generating Revenue | |||
| 5. Later Stage VC (Series E) | 05-Sep-2008 | $50M | $164M | Completed | Generating Revenue | |
| 4. Later Stage VC (Series D) | 22-Mar-2007 | $29.8M | $114M | Completed | Generating Revenue |
Chemocentryx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A3 | ||||||||
| Series A2 | 1,000,000 | $0.001000 | $1 | $1 | 1x | $1 | 1.47% | |
| Series A1 | 3,000,000 | $0.001000 | $1 | $1 | 1x | $1 | 4.41% |
Chemocentryx Comparisons
Industry
Financing
Details
Chemocentryx Competitors (21)
One of Chemocentryx’s 21 competitors is BioNTech, a Formerly VC-backed company based in Mainz, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Arno Therapeutics | Formerly VC-backed | Flemington, NJ | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
Chemocentryx Patents
Chemocentryx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023255619-A1 | Ccr4 antagonists | Pending | 19-Apr-2022 | ||
| EP-4511368-A2 | Ccr4 antagonists | Pending | 19-Apr-2022 | ||
| EP-4511368-A4 | Ccr4 antagonists | Pending | 19-Apr-2022 | ||
| JP-2023159050-A | Ccr4 antagonists | Pending | 19-Apr-2022 | ||
| US-20230382894-A1 | Ccr4 antagonists | Pending | 19-Apr-2022 | C07D403/04 |
Chemocentryx Signals
Chemocentryx Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Bio-Techne | Corporation | Minority | ||
| CSL Vifor | Corporation | Minority | ||
| GSK | Corporation | Minority | ||
| Gimv | PE/Buyout | Minority |
Chemocentryx ESG
Risk Overview
Risk Rating
Updated December, 31, 2022
32.89 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,669
Rank
Percentile
Pharmaceuticals
Industry
of 895
Rank
Percentile
Biotechnology
Subindustry
of 396
Rank
Percentile
Chemocentryx FAQs
-
When was Chemocentryx founded?
Chemocentryx was founded in 1997.
-
Where is Chemocentryx headquartered?
Chemocentryx is headquartered in Mountain View, CA.
-
What is the size of Chemocentryx?
Chemocentryx has 178 total employees.
-
What industry is Chemocentryx in?
Chemocentryx’s primary industry is Drug Discovery.
-
Is Chemocentryx a private or public company?
Chemocentryx is a Private company.
-
What is the current valuation of Chemocentryx?
The current valuation of Chemocentryx is .
-
What is Chemocentryx’s current revenue?
The current revenue for Chemocentryx is .
-
How much funding has Chemocentryx raised over time?
Chemocentryx has raised $316M.
-
Who are Chemocentryx’s investors?
Alta Partners, Bio-Techne, CSL Vifor, GSK, and Gimv are 5 of 16 investors who have invested in Chemocentryx.
-
Who are Chemocentryx’s competitors?
BioNTech, Sangamo Therapeutics, Immunocore Holdings, Arno Therapeutics, and Bristol-Myers Squibb are some of the 21 competitors of Chemocentryx.
-
When was Chemocentryx acquired?
Chemocentryx was acquired on 20-Oct-2022.
-
Who acquired Chemocentryx?
Chemocentryx was acquired by Amgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process